We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for dostarlimab (GlaxoSmithKline Australia Pty Ltd)
Active ingredients
dostarlimab
Date of review outcome
Lapse date
Type
Priority review
Indication
JEMPERLI is indicated in combination with platinum-containing chemotherapy for the treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR)/microsatellite high (MSI-H) endometrial cancer.
Therapeutic area
Oncology